Search form
Search
contact us
Navigation
home
boards
Jobs
job ratings
cp wire
medtech news
pharmagather
catering
advertise
whistleblower info
pharmaceutical fraud
medical device | DME fraud
clinical lab fraud
False Claims Act
Legal Help
login/register
You are here
Home
»
companies
» refractory differential thyroid cancer
refractory differential thyroid cancer
U.S. FDA Approves NEXAVAR (sorafenib) for the Treatment of Patients with Locally Recurrent or Metastatic, Progressive, Differentiated Thyroid Carcinoma Refractory to Radioactive Iodine Treatment
Yahoo/PR NewsWire
Sat, 11/23/13 - 12:06 pm
Nexavar
Bayer
ONYX Pharmaceuticals
Amgen
thyroid cancer
refractory differential thyroid cancer
Bayer's Nexavar meets goal in thyroid cancer trial
Reuters
Thu, 01/3/13 - 11:34 am
Bayer
Nexavar
refractory differential thyroid cancer